NCT01101256Unknown不适用
Determination of Residual Anticoagulatory Effects of Prophylactic or Therapeutic Treatment With Fondaparinux
Johann Wolfgang Goethe University Hospital1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2010年4月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- antiXa-levels (peak- and through-levels)
研究概览
简要总结
The purpose of this study is to determine residual anticoagulatory effects of a prophylactic or therapeutic fondaparinux treatment i.e. prior to surgery/intervention, after pause of therapy etc.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fondaparinux therapy for at least 3 days
排除标准
- •Age < 18 years
- •Hemodialysis
结局指标
主要结局
antiXa-levels (peak- and through-levels)
时间窗: between day 3 and day 14 after start of therapy
次要结局
- thromboembolic or bleeding episodes, HIT(day 14 after start of therapy)
研究者
研究点 (1)
Loading locations...
相似试验
终止
4 期
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)COVID-19NCT04406389Weill Medical College of Cornell University14
尚未招募
不适用
Assessing the correlations of anticoagulant effects between Thromboelastography [TEG] and anti-Xa activity in patients on therapeutic dose of low-molecular-weight heparin (LMWH)?Blood - Other blood disordersAcute coronary syndromeACTRN12609000055202Hayden White60
已完成
不适用
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care UnitsCovid19NCT04829552William Beaumont Hospitals704
招募中
3 期
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGBleedingStrokeAtrial FibrillationNCT04045665Icahn School of Medicine at Mount Sinai3,200
已完成
4 期
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19COVID-19Venous ThrombosesArterial ThrombosisNCT04367831Columbia University94